Publications by authors named "Francois Le Grand"
Personalized oncology with artificial intelligence: The case of temozolomide.
Artif Intell Med
August 2019
Purpose: Using artificial intelligence techniques, we compute optimal personalized protocols for temozolomide administration in a population of patients with variability.
Methods: Our optimizations are based on a Pharmacokinetics/Pharmacodynamics (PK/PD) model with population variability for temozolomide, inspired by Faivre et al. [10] and Panetta et al.
Optimizing treatment combination for lymphoma using an optimization heuristic.
Math Biosci
September 2019
Background: The standard treatment for high-grade non-Hodgkin lymphoma involves the combination of chemotherapy and immunotherapy. We characterize in-silico the optimal combination protocol that maximizes the overall survival probability. We rely on a pharmacokinetics/pharmacodynamics (PK/PD) model that describes the joint evolution of tumor and effector cells, as well as the effects of both chemotherapy and immunotherapy.
View Article and Find Full Text PDFArticle Synopsis
- Researchers developed an optimal injection pattern for anti-VEGF treatment and its combination with unlicensed dendritic cells to enhance tumor eradication.
- The study used a mathematical model to simulate tumor growth, angiogenesis, and immune responses, employing a Monte-Carlo tree search algorithm to minimize total drug doses needed for successful treatment.
- Key findings show that optimized protocols significantly reduce drug doses required, with some combinations eradicating tumors with only a fraction of standard doses, and they also allow for later diagnosis dates without increasing drug amounts.
We determine an optimal protocol for temozolomide using population variability and dynamic optimization techniques inspired by artificial intelligence. We use a Pharmacokinetics/Pharmacodynamics (PK/PD) model based on Faivre and coauthors (Faivre, et al., 2013) for the pharmacokinetics of temozolomide, as well as the pharmacodynamics of its efficacy.
View Article and Find Full Text PDFArticle Synopsis
- The study compares Maximum Tolerated Dose (MTD) and Metronomic Chemotherapy (MC) protocols for temozolomide, aiming to identify optimal chemotherapy regimens.
- A pharmacokinetics/pharmacodynamics model is used to evaluate drug efficacy and toxicity, including myelosuppression caused by temozolomide.
- Findings indicate that the MC regimen can lower toxicity without losing efficacy, while the MTD protocol faces trade-offs between improved efficacy and increased toxicity, paving the way for customized treatment plans.